Cost-effectiveness thresholds or decision-making threshold: a novel perspective.
Cost Eff Resour Alloc
; 21(1): 72, 2023 Oct 03.
Article
em En
| MEDLINE
| ID: mdl-37789326
ABSTRACT
The use of multiple cost-effectiveness thresholds in pharmacoeconomic evaluation is a hotly debated topic in the international academic community. This study analyzed and discussed thresholds in the context of pharmacoeconomic evaluation and reimbursement decision-making. We suggest that the thresholds inferred from reimbursement decisions should be distinguished from cost-effectiveness threshold in pharmacoeconomic evaluation. Pharmacoeconomic evaluations should adopt a fixed threshold, which should not vary with the subjects evaluated. This would help avoid the invitation of numerous cost-effectiveness thresholds for a specific drug, an exceptional disease, a type of innovation, or a certain level of malignancy, which misleads economic evaluation adopting restless changing standards and making pharmacoeconomic evaluation and decision-making more complex and contradictory.
Texto completo:
1
Bases de dados:
MEDLINE
Tipo de estudo:
Health_economic_evaluation
Idioma:
En
Revista:
Cost Eff Resour Alloc
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
China